

Targetry Development at HZDR: Radiometal Production with the TR-Flex Cyclotron



Santiago Andrés Brühlmann, Martin Walther and Martin Kreller

¹ Helmholtz-Zentrum Dresden-Rossendorf, Institute of Radiopharmaceutical Cancer Research, Department of Targetry, Target Chemistry and Radiopharmacy; 01328 Dresden, Germany

Produced Radionuclides and their Uses

SPECT Radionuclides:

Diagnostics through Single Photon Emission Computed Tomography (SPECT).

⁶⁷Ga
78.28 h
ε 100 %

y-lines:
93.3 keV (39 %),
185 keV (21 %),
300 keV (17 %),
i.a.
MAE & CE:
0.99 keV (168 %, AU L),
7.5 keV (61 %, AU K),
84 keV (28 %, CE K),
i.a.

¹³¹Ba
11.50 d
ε 100 %

y-lines:
496 keV (48 %),
124 keV (30 %),
216 keV (20 %),
371 keV (14 %),
i.a.

Theranostic Matched Pair

PET Radionuclides:

The emitted radiation (β⁺-particles, i.e. 511 keV γ-rays) is used for **diagnostics** through Positron Emission Tomography (PET).

⁶¹Cu
3.339 h
β⁺ 61.4 %
ε 38.6 %

β⁺-emission:
E_{β⁺,mean} = 499 keV
y-lines:
283 keV (12.7 %),
656 keV (10.4 %),
i.a.

⁶⁴Cu
12.70 h
β⁺ 38.5 %
β⁺ 17.5 %
ε 44.0 %

β⁺-emission:
E_{β⁺,mean} = 278 keV
E_{β⁺,mean} = 190 keV
y-lines:
1346 keV (0.472 %)

Perfect Theranostic Matched Pair

Therapeutic Radionuclides:

Radionuclides that can be used for **therapy** via the emission of electrons, i.e. β⁻-particles, conversion electrons (CE) or Meitner-Auger electrons (MAE).

⁸⁹Zr
78.41 h
β⁺ 22.7 %
ε 77.3 %

β⁺-emission:
E_{β⁺,mean} = 396 keV
y-lines:
909 keV (99 %),
1713 keV (0.75 %)

¹³³La
3.912 h
β⁺ 7.1 %
ε 92.9 %

β⁺-emission:
E_{β⁺,mean} = 463 keV
y-lines:
279 keV (2.4 %),
302 keV (1.6 %),
290 keV (1.4 %),
i.a.

(Perfect) Theranostic Matched Pair

⁶⁷Cu
61.83 h
β⁻ 100 %

β⁻-emission:
E_{β⁻,mean} = 141 keV
y-lines:
185 keV (49 %),
93.3 keV (16 %),
i.a.

¹³⁵La
19.5 h
ε 100 %
MAE

MAE & CE:
3.7 keV (78 %, AU L),
8.5 keV (50 %, AU K),
i.a.
y-lines:
480 keV (1.5%),
Minor γ-lines

^{197m}Hg
23.8 h
IT 91.4 %
ε 8.6 %

MAE & CE:
7.6 keV (71 %, AU L),
150 keV (50 %, CE L),
119 keV (33 %, CE L),
82 keV (20 %, CE K),
i.a.
y-lines:
134 keV (34%),
279 keV (6.1 %)

¹⁹⁷Hg
64.1 h
ε 100 %

MAE & CE:
7.4 keV (119 %, AU L),
63 keV (60 %, CE L),
74 keV (33 %, CE M),
i.a.
y-lines:
77 keV (19 %)

Radionuclide properties from IAEA Nuclear Data Services [1].

Irradiation Conditions and Simulations

The Target Cycle:

Three different types of solid targets are used at the HZDR: metallic foils (for ⁸⁹Zr & ^{197m}Hg), electroplated targets (for ^{61/64}Cu, ⁶⁷Cu & ⁶⁷Ga) and powder targets (for ¹³¹Ba & ^{133/135}La). Due to the high costs of the enriched target materials, usually a recycling strategy is performed (exemption Y for ⁸⁹Zr, Cs for ¹³¹Ba & Au for ^{197m}Hg).

Why enriched targets?

The TR-Flex Cyclotron:

The target irradiations are performed at the TR-Flex Cyclotron, which features a proton energy of 16 – 30 MeV and a current of up to 300 μA.

TR-FLEX Cyclotron: irradiation beam. The solid target stations offers a 90° and a 30° configurations, but further development is on the way...

Solid target irradiation configurations: 90° and 30°. The tilted target configuration increases the irradiated area thus improving the cooling of the target.

In-house developed Aluminum degrader allows the irradiation with proton energies down to 13 MeV [2].

Autradiographic measurement of an irradiated gold disk at the 90°-solid state target, beam energy 30 MeV [2].

COMSOL (<https://www.comsol.com/>) simulation of the 30° solid target cooling. The target is cooled on the front with helium (left) and with water on the back (right). The velocity profile of the cooling fluids obtained from the simulation is shown.

Parameter Optimization – Simulations:

Simulations allow the optimization of the irradiation parameters, i.e. proton beam energy and current, to maximize the radionuclide production. Studies of the backing material are also performed to guarantee the target integrity as well as reducing the activation the backing itself.

⁶¹Cu saturation yield for proton irradiation of a ⁶²Ni target as a function of the incident beam energy. In red, the gold, used as the heat source for the incident energy resulting in an exiting energy greater than thermal simulations of the ⁶⁷Ga and ¹⁶⁵MeV, which would highly activate the gold backing [3].

Temperature profile parallel (left) and normal (right) to the beam of the 30° ⁶⁷Cu targets while being bombarded with a proton current of 60 μA and 16.8 MeV. Gold and Silver are studied as backings.

Temperature profile parallel (left) and normal (right) to the beam of the 90° ¹³³La target while being bombarded with 18.7 MeV protons and different currents.

Yields and Product Characterization

Radionuclide	Nuclear Reaction	Irradiation Parameters	Typical Activities @EOP	Typical Saturation Yield @EOB
⁶¹ Cu 3.339 h β ⁺ 61.4 % ε 38.6 %	⁶² Ni(p,2n) ⁶¹ Cu	20.8 – 18.7 MeV, 70 μA, 1 – 2 h	5 – 10 GBq	1300 MBq/μA [3]
⁶⁴ Cu 12.70 h β ⁺ 38.5 % β ⁺ 17.5 % ε 44.0 %	⁶⁴ Ni(p,n) ⁶⁴ Cu	13.5 MeV, 70 μA, 2 – 2.5 h	20 – 30 GBq	5000 MBq/μA [4]
⁶⁷ Cu 61.83 h β ⁻ 100 %	⁷⁰ Zn(p,α) ⁶⁷ Cu	16.8 MeV, 60 μA, 10 – 30 h (in 2/3 days)	400 – 1200 MBq	90 MBq/μA [5,6]
¹³³ La 3.912 h β ⁺ 7.1 % ε 92.9 %	¹³⁴ Ba(p,2n) ¹³³ La	18.7 MeV, 60 μA, 0.5 – 1 h	1 – 4 GBq	660 MBq/μA [7,8]
¹³⁵ La 19.5 h ε 100 % MAE	¹³⁶ Ba(p,2n) ¹³⁵ La	18.7 MeV, 60 μA, 0.5 – 1 h	1 – 2 GBq	800 MBq/μA
⁶⁷ Ga 78.28 h ε 100 %	⁶⁸ Zn(p,2n) ⁶⁷ Ga	19 MeV, 35 μA, 1.5 – 2 h	600 – 1600 MBq	2600 MBq/μA [4]
¹³¹ Ba 11.50 d ε 100 %	¹³³ Cs(p,3n) ¹³¹ Ba	27.5 MeV, 20 μA, 2 – 4 h	150 – 250 MBq	1200 MBq/μA [4]
¹⁹⁷ Hg 64.1 h ε 100 %	¹⁹⁷ Au(p,p,n) ^{197m} Hg	13 MeV, 45 μA, 1 – 3 h	250 / 300 MBq	100 / 215 MBq/μA
⁸⁹ Zr 78.41 h β ⁺ 22.7 % ε 77.3 %	⁸⁹ Y(p,n) ⁸⁹ Zr	11.0 MeV, 35 μA, 1h - 1.5 h	300 – 400 MBq	3000 MBq/μA

Gamma-spectroscopy of the product [¹³³La]LaCl₃ solution.

Gamma-spectroscopy of the [⁶¹Cu]CuCl₂ product solution.

Gamma-spectroscopy of the [⁶⁷Cu]CuCl₂ product solution.

References:

[1] IAEA Nuclear Data Services, <https://www-nds.iaea.org/>, last accessed on 08.09.2023.

[2] Kreller, M.; Knieß, T.; Preusche, S. *Proceedings of the 22nd International Conf. on Cyclotrons and Their Applications* **2019**, 23-27.

[3] Brühlmann, S.A.; Walther, M.; Kopka, K.; Kreller, M. *EJNMMI radiopharm. chem.* **2024**, 9, 3.

[4] Kreller, M.; Brühlmann, S.A.; Knieß, T.; Kopka, K.; Walther, M. *Instruments* **2024**, 8, 10.

[5] Brühlmann, S.A.; Walther, M.; Kreller, M.; Reissig, F.; Pietzsch, H.-J.; Kniess, T.; Kopka, K. *Pharmaceuticals* **2023**, 16, 314.

[6] Brühlmann, S.A.; Walther, M.; Zhutova, N.; Kopka, K.; Kreller, M. *Radiochim. Acta.* **2025**, 10.1515/ract-2025-0083.

[7] Brühlmann, S.A.; Kreller, M.; Pietzsch, H.-J.; Kopka, K.; Mamat, C.; Walther, M.; Reissig, F. *Pharmaceuticals* **2022**, 15, 1167.

[8] Brühlmann, S.A.; Walther, M.; Blei, M.K.; Mamat, C.; Kopka, K.; Freudenberger R.; Kreller, M. *EJNMMI radiopharm. chem.* **2024** 9, 60.

Acknowledgements:

We would like to acknowledge the TR-Flex Cyclotron technical team and the assistance during the radiochemical processing performed by: Sandra Hübner, Christian Jentschel, Marcus Lösel, Jens Reinhardt and Jan Roßig. Moreover, we would like to thank Dr. Steffen Happel from Triskem for providing the used chromatographic resins and the advantageous insights and discussions.

